Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
Latest Video
New Stories
-
API moves on Sigma
December 14, 2018 - - Latest News -
February push could avoid parliamentary scrutiny
December 14, 2018 - - Latest News -
New health program highlights PBS challenge
December 14, 2018 - - Latest News -
Pharmaxis reports first US sales of Aridol
December 14, 2018 - - Latest News -
Insurers: Use PBS as the model for devices
December 13, 2018 - - Latest News -
Bayer backing new kidney disease trial
December 13, 2018 - - Latest News -
$100,000 the goal for #PharmaCup2019
December 13, 2018 - - Latest News